BeiGene lines up a next-gen CTLA-4 to complement its PD-1 pillar in new deal worth up to $270M

BeiGene is jumping on the bandwagon for PD-(L)1/CTLA-4 combos ? with a twist.

Through a development and commercialization pact with San Diego-based BioAtla, BeiGene is pairing its PD-1 drug tislelizumab with BA3071, a CTLA-4 blocking ?conditionally active biologic? that gets turned on or off based on whether it?s inside the tumor microenvironment.

Scott Smith

San Diego-based BioAtla is responsible for early clinical work, while BeiGene will lead the joint efforts thereafter to develop the combo and deal with regulators around the world. The Chinese biotech, which is committing